Craig H Moskowitz Selected Research

Brentuximab Vedotin

12/2021	Brentuximab vedotin in combination with nivolumab in relapsed or refractory Hodgkin lymphoma: 3-year study results.
10/2021	Brentuximab Vedotin Combined With Chemotherapy in Patients With Newly Diagnosed Early-Stage, Unfavorable-Risk Hodgkin Lymphoma.
1/2020	Pembrolizumab monotherapy in patients with primary refractory classical hodgkin lymphoma who relapsed after salvage autologous stem cell transplantation and/or brentuximab vedotin therapy: KEYNOTE-087 subgroup analysis.
1/2020	KEYNOTE-013 4-year follow-up of pembrolizumab in classical Hodgkin lymphoma after brentuximab vedotin failure.
12/2018	Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse.
1/2018	Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma.
7/2017	Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma.
12/2016	Quality of life results from a phase 3 study of brentuximab vedotin consolidation following autologous haematopoietic stem cell transplant for persons with Hodgkin lymphoma.
11/2016	Programmed Death-1 Blockade With Pembrolizumab in Patients With Classical Hodgkin Lymphoma After Brentuximab Vedotin Failure.
1/2016	Brentuximab vedotin and AVD followed by involved-site radiotherapy in early stage, unfavorable risk Hodgkin lymphoma.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Craig H Moskowitz Research Topics

Disease

46	Hodgkin Disease (Hodgkin's Disease) 01/2022 - 03/2004
25	Lymphoma (Lymphomas) 01/2022 - 09/2002
21	Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse) 12/2019 - 09/2003
14	Neoplasms (Cancer) 01/2022 - 03/2004
9	Non-Hodgkin Lymphoma (Lymphosarcoma) 10/2021 - 11/2004
8	B-Cell Lymphoma (Lymphoma, B Cell) 01/2022 - 09/2005
5	Follicular Lymphoma (Lymphoma, Small Cleaved Cell, Follicular) 01/2020 - 09/2009
3	Nausea 12/2021 - 03/2015
3	Hematologic Neoplasms (Hematological Malignancy) 01/2020 - 11/2016
3	Anaplastic Large-Cell Lymphoma (Ki 1 Lymphoma) 03/2015 - 07/2006
3	T-Cell Lymphoma (Lymphoma, T Cell) 12/2013 - 11/2007
3	Mantle-Cell Lymphoma (Lymphoma, Mantle Cell) 04/2011 - 11/2004
2	Hypertension (High Blood Pressure) 01/2022 - 08/2017
2	Exanthema (Rash) 01/2022 - 01/2019
2	Anemia 01/2019 - 08/2017
2	Disease Progression 10/2018 - 11/2016
2	Peripheral T-Cell Lymphoma (Lymphoma, T Cell, Peripheral) 09/2009 - 07/2006
1	Hyperglycemia 01/2022
1	Diarrhea 01/2022
1	Pruritus (Itching) 01/2022
1	Dermatitis 01/2022
1	Marginal Zone B-Cell Lymphoma (MALT Lymphoma) 01/2021
1	Bites and Stings (Sting) 12/2019
1	Second Primary Neoplasms (Neoplasms, Second) 10/2019
1	Thyroiditis 01/2019
1	Colitis 01/2019
1	Pneumonia (Pneumonitis) 01/2019
1	Hyperhidrosis 08/2017
1	Multiple Myeloma 08/2017
1	Leukemia 10/2016
1	Acquired Immunodeficiency Syndrome (AIDS) 10/2016

Drug/Important Bio-Agent (IBA)

16	Brentuximab VedotinIBA 12/2021 - 06/2012
14	Rituximab (Mabthera)FDA Link 01/2020 - 09/2002
9	pembrolizumabIBA 10/2021 - 11/2016
7	Cyclophosphamide (Cytoxan)FDA LinkGeneric 01/2017 - 04/2005
5	Doxorubicin (Adriamycin)FDA LinkGeneric 01/2018 - 04/2005
5	Vincristine (Oncovin)FDA LinkGeneric 12/2015 - 04/2005
4	NivolumabIBA 12/2021 - 01/2018
4	Etoposide (VP 16)FDA LinkGeneric 03/2015 - 05/2013
4	Prednisone (Sone)FDA LinkGeneric 04/2011 - 04/2005
3	ibrutinibIBA 01/2022 - 01/2017
3	PlatinumIBA 01/2022 - 07/2013
3	Fluorodeoxyglucose F18 (Fludeoxyglucose F 18)FDA Link 01/2022 - 01/2014
3	Immunoconjugates (Immunoconjugate)IBA 12/2019 - 02/2015
3	Monoclonal AntibodiesIBA 01/2018 - 07/2013
3	Bendamustine Hydrochloride FDA Link 08/2017 - 02/2013
3	Carboplatin (JM8)FDA LinkGeneric 03/2015 - 07/2013
3	Methotrexate (Mexate)FDA LinkGeneric 02/2015 - 11/2003
3	IceIBA 12/2013 - 05/2004
3	Cytarabine (Cytosar-U)FDA LinkGeneric 07/2013 - 11/2003
2	Agammaglobulinaemia Tyrosine KinaseIBA 01/2022 - 01/2017
2	Gemcitabine FDA Link 10/2021 - 02/2013
2	Busulfan (Busulfex)FDA Link 01/2017 - 02/2015
2	Thiotepa (Triethylenethiophosphoramide)FDA LinkGeneric 01/2017 - 02/2015
2	Anaplastic Lymphoma KinaseIBA 12/2013 - 07/2006
2	Ifosfamide FDA LinkGeneric 12/2013 - 07/2013
2	Bortezomib (Velcade)FDA Link 04/2011 - 11/2004
2	10-propargyl-10-deazaaminopterin FDA Link 09/2009 - 11/2007
2	Reduced Folate Carrier ProteinIBA 09/2009 - 11/2007
1	NVP-BKM120IBA 01/2022
1	Adrenal Cortex Hormones (Corticosteroids)IBA 12/2021
1	liposomal doxorubicin (Doxil)FDA Link 10/2021
1	Vinorelbine (Navelbine)FDA LinkGeneric 10/2021
1	Chimeric Antigen ReceptorsIBA 12/2019
1	Immune Checkpoint InhibitorsIBA 10/2019
1	L-Lactate Dehydrogenase (Lactate Dehydrogenase)IBA 01/2019
1	EnzymesIBA 01/2019
1	Biological ProductsIBA 01/2019
1	RNA (Ribonucleic Acid)IBA 12/2018
1	Formaldehyde (Formol)FDA Link 12/2018
1	Heme (Haem)IBA 12/2018
1	ParaffinIBA 12/2018
1	DNA (Deoxyribonucleic Acid)IBA 12/2018
1	B7-H1 AntigenIBA 01/2018
1	Dacarbazine (DIC)FDA LinkGeneric 01/2018
1	Vinblastine (Vinblastine Sulfate)FDA Link 01/2018
1	Bleomycin (Blenoxane)FDA LinkGeneric 01/2018
1	Alkylating AgentsIBA 08/2017
1	veliparibIBA 08/2017
1	Poly(ADP-ribose) Polymerase InhibitorsIBA 08/2017
1	Proteins (Proteins, Gene)FDA Link 01/2017
1	B-Cell Antigen Receptors (B Cell Antigen Receptors)IBA 01/2017
1	LigandsIBA 11/2016
1	Granulocyte Colony-Stimulating Factor (G-CSF)IBA 10/2016
1	Prednisolone (Predate)FDA LinkGeneric 12/2015

Therapy/Procedure

39	Therapeutics 10/2021 - 09/2002
33	Drug Therapy (Chemotherapy) 01/2022 - 09/2003
26	Stem Cell Transplantation 10/2021 - 09/2002
11	Transplantation 01/2019 - 11/2003
9	Radiotherapy 01/2021 - 04/2008
7	Salvage Therapy 12/2021 - 02/2015
6	Autologous Transplantation 01/2019 - 07/2006
5	Chemoradiotherapy 10/2018 - 03/2004
4	Cell Transplantation 01/2021 - 05/2013
3	Immunotherapy 01/2021 - 01/2019
2	Aftercare (After-Treatment) 10/2019 - 05/2015
2	Hematopoietic Stem Cell Transplantation 12/2018 - 08/2010
1	Bone Marrow Transplantation (Transplantation, Bone Marrow) 01/2017
1	Lymphatic Irradiation 01/2017
1	Combination Drug Therapy (Combination Chemotherapy) 10/2016